Form 4: Anixa Director Exercises Stock Options

Anixa Biosciences Director Lewis H. Titterton Jr. exercised 16,000 employee stock options at $2.92 per share, increasing his direct common stock holdings.

Summary

• Lewis H. Titterton Jr., a Director of Anixa Biosciences Inc. (ANIX), reported an insider transaction on December 15, 2025.
• The transaction involved the exercise of 16,000 employee stock options.
• These options were granted on February 18, 2016, and had an expiration date of February 18, 2026.
• The exercise price for the options was $2.92 per share.
• Following the exercise, Mr. Titterton Jr. directly beneficially owns 969,334 shares of Anixa Biosciences Inc. common stock.
• He no longer holds any derivative securities related to this specific option grant.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A director increasing their direct ownership through option exercise typically signals confidence in the company's future prospects and valuation, as they are converting derivative securities into direct equity at a set price.

Positives

• A Director, Lewis H. Titterton Jr., increased his direct beneficial ownership of Anixa Biosciences Inc. common stock by 16,000 shares, signaling confidence in the company's future prospects.
• The exercise price of $2.92 per share indicates that the options were in-the-money, suggesting a favorable market price relative to the grant price.

Future Outlook

This Form 4 filing reports a past insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider transactions, such as the exercise of stock options by a director, are routine disclosures in the biotechnology and pharmaceutical industry, as in other sectors. They provide transparency into management's direct financial interest in the company's performance.

Stakeholder Impact

• Shareholders may view the director's increased direct ownership as a positive signal of management's belief in the company's value and future performance.

Key Dates

Keywords

Anixa Biosciences, ANIX, Form 4, insider transaction, stock option exercise, director ownership, beneficial ownership